Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Major Depressive Disorder Market Expected To Grow In Terms Of Size?

The market size for major depressive disorder has been progressively increasing over the past few years. It is anticipated to expand from $6.12 billion in 2024 to $6.26 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 2.3%. The expansion during the preceding period was driven by advancements in pharmaceuticals, an increased understanding of mental health, various psychological therapies, and the promotion of public health initiatives.

In the coming years, the market size for major depressive disorder is set for consistent growth, predicted to reach $7.14 billion by 2029 with a compound annual growth rate (CAGR) of 3.4%. The projected growth within the forecast period can be linked to developments in precision medicine, telepsychiatry and teletherapy, new treatment methods, and the worldwide expansion of mental health services. Key trends for the forecast period include early intervention, the establishment of peer support and online communities, comprehensive approaches, as well as resilience and coping strategies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Are The Primary Factors Supporting The Major Depressive Disorder Market Expansion?

The escalation in occurrences of substance misuse and alcohol consumption is predicted to boost the expansion of the market for major depressive disorder. Substance and alcohol misuse are identified as the patterns of overuse and damaging use of substances, incorporating alcohol, which can result in adverse physical, mental, and social effects. These conditions often collectively appear with major depressive disorder and these disorders tend to mutually enhance each other, drastically escalating the possibility of physical and mental damage. For instance, a survey conducted by the Substance Abuse and Mental Health Services Administration, a US-based health and human services department, revealed in July 2024 that 3.1% of people, which equates to 8.9 million individuals, abused opioids in 2023. Furthermore, 21.8% of individuals over the age of 12 consumed marijuana, making it the most frequently used illegal drug. Also, data showed a rise in the vaping of nicotine in the past month by 9.4% of people over the age of 12, which is an increase from 8.3% in 2022. As such, the escalating occurrences of substance misuse and alcohol consumption are fueling the expansion of the major depressive disorder market.

Which Segmentation Categories Are Highlighted In The Major Depressive Disorder Market Analysis?

The major depressive disordermarket covered in this report is segmented –

1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments

2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis

3) By End-User: Clinics; Hospitals; Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Dialectical Behavior Therapy (DBT); Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT; Bilateral ECT; Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS); Deep Transcranial Magnetic Stimulation (dTMS); Theta Burst Stimulation (TBS); Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT); Psychodynamic Therapy; Interpersonal Therapy (IPT); Vagus Nerve Stimulation (VNS); Ketamine Therapy; Bright Light Therapy; Psychedelic-Assisted Therapy; Medication (Antidepressants)

Which Market Trends Are Expected To Define The Future Of The Major Depressive Disorder Market?

Primary corporations in the major depressive disorder industry concentrate on creating novel products and securing their approvals to establish a competitive edge. The rise in drug approvals for treating major depressive disorder, such as VRAYLAR (cariprazine), is due to the demand for safer and more potent treatments. For instance, in December 2022, AbbVie Inc., a pharmaceutical firm based in the US, attained approval for VRAYLAR (cariprazine) from the Food and Drug Administration (FDA), a US federal agency, as an adjunctive therapy alongside antidepressants for adults with major depressive disorder (MDD). VRAYLAR is an avant-garde atypical antipsychotic medication that regulates levels of dopamine and serotonin in the brain. It is the inaugural atypical antipsychotic to receive approval as supplementary treatment for major depressive disorder. Furthermore, it comes in capsule form and is intended for once-a-day use.

Which Organizations Are At The Forefront Of The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2025, By The Business Research Company

Mental Health Apps Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mental-health-apps-global-market-report

Behavioral And Mental Health Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/behavioral-and-mental-health-software-global-market-report

Residential Substance Abuse And Mental Health Facilities Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model